Original language | English (US) |
---|---|
Pages (from-to) | 1797-1800 |
Number of pages | 4 |
Journal | Molecular Therapy |
Volume | 30 |
Issue number | 5 |
Early online date | Feb 28 2022 |
DOIs |
|
State | Published - May 4 2022 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Molecular Therapy, Vol. 30, No. 5, 04.05.2022, p. 1797-1800.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - A systematic approach to identify host targets and rapidly deliver broad-spectrum antivirals
AU - Olivet, Julien
AU - Maseko, Sibusiso B.
AU - Volkov, Alexander N.
AU - Salehi-Ashtiani, Kourosh
AU - Das, Kalyan
AU - Calderwood, Michael A.
AU - Twizere, Jean Claude
AU - Gorgulla, Christoph
N1 - Funding Information: J.O. thanks Wallonie-Bruxelles International (WBI-World Excellence Fellowship), the Belgian F.R.S.-FNRS-Télévie (FC27371, Crédit no. 7454518F), and the Rega Institute for Medical Research, KU Leuven for the financial support. This work was in part supported by NIAID R21 AI153738 awarded to M.A.C. and by the NYU Abu Dhabi Faculty Research Fund AD060 awarded to K.S.-A. J.-C.T. is a Maître de Recherche of the Belgian F.R.S.-FNRS. C.G. thanks ChemAxon for a free academic license. This work was in part supported by NIH grants CA200913, AI037581, and GM129026 awarded to Gerhard Wagner, as well as by the ARO grant W911NF1910302 to Arthur Jaffe. J.O. J.-C.T. and C.G. wrote the manuscript with critical insight from S.B.M. A.N.V. K.S.-A. K.D. and M.A.C. All authors discussed the proposed methodology and experimental approaches. C.G. is the cofounder of two companies, Virtual Discovery, Inc. and Quantum Therapeutics, Inc. which are engaged in drug discovery activities, in part using VirtualFlow. Funding Information: J.O. thanks Wallonie-Bruxelles International (WBI-World Excellence Fellowship), the Belgian F.R.S.-FNRS-Télévie (FC27371, Crédit no. 7454518F ), and the Rega Institute for Medical Research, KU Leuven for the financial support. This work was in part supported by NIAID R21 AI153738 awarded to M.A.C. and by the NYU Abu Dhabi Faculty Research Fund AD060 awarded to K.S.-A. J.-C.T. is a Maître de Recherche of the Belgian F.R.S.-FNRS. C.G. thanks ChemAxon for a free academic license. This work was in part supported by NIH grants CA200913 , AI037581 , and GM129026 awarded to Gerhard Wagner, as well as by the ARO grant W911NF1910302 to Arthur Jaffe.
PY - 2022/5/4
Y1 - 2022/5/4
UR - http://www.scopus.com/inward/record.url?scp=85125471926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125471926&partnerID=8YFLogxK
U2 - 10.1016/j.ymthe.2022.02.015
DO - 10.1016/j.ymthe.2022.02.015
M3 - Comment/debate
C2 - 35231394
AN - SCOPUS:85125471926
SN - 1525-0016
VL - 30
SP - 1797
EP - 1800
JO - Molecular Therapy
JF - Molecular Therapy
IS - 5
ER -